Dementia diet: Drink costing less than £4 has been shown to delay onset of Alzheimer's

DEMENTIA risk is known to be reduced by omega-3. Now researchers have created a drink containing fatty acids, vitamins and other nutrients that they say slows onset of Alzheimer ’s disease.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news

Related Links:

AbstractData Mining in medicine is an emerging field of great importance to provide a prognosis and deeper understanding of disease classification, specifically in Mental Health areas. The main objective of this paper is to present a review of the existing research works in the literature, referring to the techniques and algorithms of Data Mining in Mental Health, specifically in the most prevalent diseases such as: Dementia, Alzheimer, Schizophrenia and Depression. Academic databases that were used to perform the searches are Google Scholar, IEEE Xplore, PubMed, Science Direct, Scopus and Web of Science, taking into accou...
Source: Journal of Medical Systems - Category: Information Technology Source Type: research
Publication date: Available online 20 July 2018Source: Alzheimer's &DementiaAuthor(s): Juan Antonio García-León, Alfredo Cabrera-Socorro, Kristel Eggermont, Ann Swijsen, Joke Terryn, Raheem Fazal, FatemehArefeh Nami, Laura Ordovás, Ana Quiles, Frederic Lluis, Lutgarde Serneels, Keimpe Wierda, Annerieke Sierksma, Mohamed Kreir, Francisco Pestana, Philip Van Damme, Bart De Strooper, Lieven Thorrez, Andreas Ebneth, Catherine M. VerfaillieAbstractTauopathies are neurodegenerative diseases characterized by TAU protein–related pathology, including frontotemporal dementia and Alzheimer's disease amo...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
See something of interest? Please share our postings with colleagues in your institutions! Spotlight The MAReport: Check out the Spring 2018 issue of the MAReport newsletter! This quarter, Academic Coordinator Elaina Vitale talked about using evidence-based resources to improve citations on Wikipedia, and her experience with NNLM’s first virtual Wikipedia Edit-a-thon. National Network of Libraries of Medicine News Dementia and Alzheimer’s Services @ Your Library – Midwest Matters, from GMR The next round of PubMed for Librarians begins August 29. Register for any (or all) of the PML classes to learn ...
Source: NN/LM Middle Atlantic Region Blog - Category: Databases & Libraries Authors: Tags: Weekly Postings Source Type: news
Conditions:   Sleep Disorder;   Complaint, Subjective Health Interventions:   Behavioral: Pittsburgh Sleep Quality Index;   Behavioral: Sleep diary;   Behavioral: Katz Index of Independence in Activities of Daily Living;   Behavioral: Lawton Instrumental Activities of Daily Living;   Behavioral: Neuropsychiatric Inventory (Cummings);   Behavioral: Mini Zarit Caregiver Burden Scale, for the caregiver;   Behavioral: Mini Mental state examination;   Behavioral: Cornell Scale for Depression in Demen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Alzheimer Disease Intervention:   Drug: Brexpiprazole Sponsors:   Otsuka Pharmaceutical Development&Commercialization, Inc.;   H. Lundbeck A/S Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Sleep Disorder;   Complaint, Subjective Health Interventions:   Behavioral: Pittsburgh Sleep Quality Index;   Behavioral: Sleep diary;   Behavioral: Katz Index of Independence in Activities of Daily Living;   Behavioral: Lawton Instrumental Activities of Daily Living;   Behavioral: Neuropsychiatric Inventory (Cummings);   Behavioral: Mini Zarit Caregiver Burden Scale, for the caregiver;   Behavioral: Mini Mental state examination;   Behavioral: Cornell Scale for Depression in Demen...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Alzheimer Disease Intervention:   Drug: Brexpiprazole Sponsors:   Otsuka Pharmaceutical Development&Commercialization, Inc.;   H. Lundbeck A/S Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Roche announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys ® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF. These in vitro diagnostic immunoassays are for the measurement of the ß-Amyloid (1-42) and Phospho-Tau concentrations in cerebrospinal fluid (CSF) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s dis ease (AD) or other causes of dementia.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
ConclusionsTau PET tracers have enabled in vivo quantification of PHF-tau burden in human brains. Tau PET can help in understanding the underlying cause of dementia symptoms, and in patient selection for clinical trials of anti-dementia therapies.
Source: Clinical and Translational Imaging - Category: Radiology Source Type: research
Publication date: Available online 19 July 2018Source: Spatial and Spatio-temporal EpidemiologyAuthor(s): Wei Xu, Changshan WuAbstractBased on national death certificate data during 2000 and 2010, we employed the space-time scan statistic to identify spatiotemporal clusters of dementia mortality in the contiguous United States. Results revealed that, for both Alzheimer's disease and all-cause dementia mortality in the total population, the most likely clusters occurred in the Northeast region, with lower than average relative risk. The most likely excess mortality clusters were in the Pacific Northwest and Ohio River Valle...
Source: Spatial and Spatio-temporal Epidemiology - Category: Epidemiology Source Type: research
More News: Alzheimer's | Dementia | Diets | Health | Nutrition | Omega 3 | Vitamins